Analysts rate Sonnet Biotherapeutics Holdings Inc. (SONN:NSD) with a Strong Buy rating and a $2 target

STA Research
by: STA Research
Sonnet Biotherapeutics Holdings Inc

Based on the Sonnet Biotherapeutics stock forecast from 3 analysts, the average analyst SONN stock price target is USD 2.00 over the next 12 months. Sonnet Biotherapeutics Holdings average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of SONN stock forecast is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Sonnet Biotherapeutics stock price was USD 0.22Sonnet Biotherapeutics stock price has changed by +0.01% over the past week, -0.09% over the past month and -65.84% over the last year.

Sonnet Biotherapeutics stock forecast from 4 Crowd analysts, has the average analyst SONN stock price target at USD 1.85 over the next 12 months. Sonnet Biotherapeutics Holdings average Crowd rating is Strong Buy.


About Sonnet Biotherapeutics Holdings Inc. (SONN:NSD):

Sonnet Biotherapeutics Holdings Inc. is a biopharmaceutical company that develops innovative targeted biological drugs and empowers a new wave of immune therapeutics. Sonnet Biotherapeutics Holdings Inc. was incorporated in 1999 and is headquartered in Charlotte, North Carolina, United States.



Most Recent Analyst Ratings for SONN’s stock:



What we like:

There is nothing we particularly like about the fundamentals on SONN’s stock forecast.


What we don’t like:

Poor risk adjusted returns:

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

High volatility:

The total returns for SONN stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns:

The average income yield of SONN stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.




Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.